BioNTech SE/$BNTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Ticker
$BNTX
Sector
Primary listing
Employees
6,772
Headquarters
Website
BioNTech SE Metrics
BasicAdvanced
$24B
-
-$2.79
1.31
-
Price and volume
Market cap
$24B
Beta
1.31
52-week high
$129.27
52-week low
$81.20
Average daily volume
1.3M
Financial strength
Current ratio
7.123
Quick ratio
6.89
Long term debt to equity
1.039
Total debt to equity
1.328
Interest coverage (TTM)
-54.07%
Profitability
EBITDA (TTM)
-546.938
Gross margin (TTM)
82.49%
Net profit margin (TTM)
-18.13%
Operating margin (TTM)
-24.95%
Effective tax rate (TTM)
-9.46%
Revenue per employee (TTM)
$549,500
Management effectiveness
Return on assets (TTM)
-2.30%
Return on equity (TTM)
-3.04%
Valuation
Price to revenue (TTM)
6.386
Price to book
1.28
Price to tangible book (TTM)
1.41
Price to free cash flow (TTM)
-18.39
Free cash flow yield (TTM)
-5.44%
Free cash flow per share (TTM)
-5.334
Growth
Revenue change (TTM)
3.70%
Earnings per share change (TTM)
22.84%
3-year revenue growth (CAGR)
-44.62%
3-year earnings per share growth (CAGR)
-60.90%
What the Analysts think about BioNTech SE
Analyst ratings (Buy, Hold, Sell) for BioNTech SE stock.
BioNTech SE Financial Performance
Revenues and expenses
BioNTech SE Earnings Performance
Company profitability
BioNTech SE News
AllArticlesVideos
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
Investopedia·1 month ago
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Market Watch·1 month ago
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals
Barrons·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioNTech SE stock?
BioNTech SE (BNTX) has a market cap of $24B as of January 07, 2026.
What is the P/E ratio for BioNTech SE stock?
The price to earnings (P/E) ratio for BioNTech SE (BNTX) stock is 0 as of January 07, 2026.
Does BioNTech SE stock pay dividends?
No, BioNTech SE (BNTX) stock does not pay dividends to its shareholders as of January 07, 2026.
When is the next BioNTech SE dividend payment date?
BioNTech SE (BNTX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioNTech SE?
BioNTech SE (BNTX) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.